Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide.
To investigate the relationship between acetylator phenotype and the development of procainamide (PA)-induced systemic lupus erythematosus (SLE-like syndrome, 28 patients with chronic ventricular arrhythmias treated with PA were followed for one year. The therapy was guided by plasma monitoring in all patients in order to obtain the proposed therapeutic plasma level of PA. Nine patients (30%), both slow and rapid acetylators, developed the SLE-like syndrome within one year. PA plasma levels were similar in both slow and rapid acetylators and there was no difference in total dose or duration of therapy before development of the syndrome. Thus, the acetylator phenotype is probably of no or minor predictive importance when PA therapy is guided by plasma monitoring. On the other hand, the antinuclear antibodies appeared significantly more rapidly in patients developing the syndrome and could possible be used as an indicator of the risk. The results support the hypothesis that the primary amino group structure of PA may be of importance in the induction of the SLE-like syndrome.
D000120:Acecainide / Q000097:blood; D000107:Acetylation; D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D005260:Female; D006801:Humans; D007538:Isoniazid; D008180:Lupus Erythematosus, Systemic / Q000139:chemically induced* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011342:Procainamide / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D013427:Sulfapyridine
D000974:Antibodies, Antinuclear; D000120:Acecainide; D011342:Procainamide; D007538:Isoniazid; D013427:Sulfapyridine